The rationale for combining BBI608 with checkpoint inhibitors was based on the hypothesis that inhibition of cancer stem cells and STAT3, a mechanism of tumor evasion from immune surveillance and resistance to immunotherapy, would overcome tumor resistance to immunotherapy. Here, STAT3 is linked to neoplasm.